

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K/A

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 9, 2020

Protara Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-36694 (Commission File No.)	20-4580525 (IRS Employer Identification No.)
1 Little West 12th Street New York, NY (Address of principal executive offices)		10014 (Zip Code)

Registrant's telephone number, including area code: (646) 844-0337

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	TARA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

EXPLANATORY NOTE

This Current Report on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed by Protara Therapeutics, Inc. (the “Company”) filed with the Securities and Exchange Commission on June 10, 2020 (the “Original Current Report”). The Original Current Report reported the final voting results of the Company’s 2020 Annual Meeting of Stockholders held on June 9, 2020 (the “Annual Meeting”). The purpose of this Amendment is to disclose the Company’s decision regarding how frequently it will conduct future stockholder advisory votes to approve the compensation of the Company’s named executive officers (“say on pay”).

Item 5.07 Submission of Matters to a Vote of Security Holders.

As reported in the Original Current Report, at the Annual Meeting, the Company’s stockholders that voted on proposal 4 indicated a preference, on an advisory basis, to hold the Company’s future say-on-pay advisory vote on an annual basis. In accordance with the original recommendation of the Company’s board of directors, and consistent with the stockholder voting results, on October 6, 2020, the Company’s compensation committee determined that the advisory say-on-pay vote will be conducted annually, until the next shareholder vote on the preferred frequency of shareholder advisory votes, which vote will occur no later than the Company’s 2026 Annual Meeting of Shareholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 8, 2020

Protara Therapeutics, Inc.

By: /s/ Blaine Davis
Blaine Davis
Chief Financial Officer